- Conditions
- Prostate Cancer
- Interventions
- ES414
- Biological
- Lead sponsor
- Aptevo Therapeutics
- Industry
- Eligibility
- Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- San Francisco, California • Buffalo, New York • Temple, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 362
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HER2-expressing Cancers
- Interventions
- ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more
- Conditions
- Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma
- Interventions
- Enoblituzumab, Retifanlimab, Tebotelimab
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • Ann Arbor, Michigan • Las Vegas, Nevada + 3 more
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- Odronextamab multiple dose levels
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 10
- States / cities
- Orange, California • Stanford, California • Tampa, Florida + 4 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
- Interventions
- acapatamab, Pembrolizumab, Etanercept, Cytochrome P450 (CYP) Cocktail
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 13
- States / cities
- Campbell, California • Duarte, California • Long Beach, California + 9 more
- Conditions
- Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
- Interventions
- Epcoritamab, Rituximab combined with cyclophosphamide, vincristine, and prednisone, Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone, Rituximab combined with polatuzumab, cyclophosphamide, doxorubicin, and prednisone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Newton, Massachusetts
- Conditions
- Merkel Cell Carcinoma, Small Cell Lung Cancer
- Interventions
- XmAb18087, XmAb18087 ± Pembrolizumab
- Biological · Drug
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Duarte, California • Los Angeles, California • Lebanon, New Hampshire + 3 more
- Conditions
- Chronic Kidney Disease (CKD)
- Interventions
- Vonsetamig
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 7 more
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Linvoseltamab, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Biospecimen Collection
- Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Marginal Zone Lymphoma
- Interventions
- Zanubrutinib, Rituximab, Epcoritamab
- Drug
- Lead sponsor
- Reid Merryman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Columbus, Ohio
- Conditions
- Non Small Cell Lung Cancer Metastatic
- Interventions
- Acasunlimab, Pembrolizumab
- Biological
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 6
- States / cities
- Santa Rosa, California • Fort Myers, Florida • St. Petersburg, Florida + 3 more
- Conditions
- SCLC
- Interventions
- Nivatrotamab
- Drug
- Lead sponsor
- Y-mAbs Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Atlanta, Georgia • Detroit, Michigan + 4 more
- Conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Interventions
- NEOK001, NEOK001 RDE
- Drug
- Lead sponsor
- NEOK Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 9
- States / cities
- New York, New York • Nashville, Tennessee • Austin, Texas + 4 more
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Amivantamab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Biological · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 271
- States / cities
- Jonesboro, Arkansas • Little Rock, Arkansas • Auburn, California + 229 more
- Conditions
- Multiple Myeloma (MM)
- Interventions
- Cemsidomide, Elranatamab
- Drug · Biological
- Lead sponsor
- C4 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 20
- States / cities
- Gilbert, Arizona • Sacramento, California • Santa Monica, California + 17 more
- Conditions
- Hemophilia A Without Inhibitor
- Interventions
- Eloctate Injectable Product, Emicizumab Injection [Hemlibra]
- Drug
- Lead sponsor
- Margaret Ragni
- Other
- Eligibility
- 4 Months to 4 Years · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Pittsburgh, Pennsylvania
- Conditions
- Glioblastoma, Glioblastoma Multiforme
- Interventions
- EGFR BATs with TMZ following SOC RT/TMZ, Weekly EGFR BATs following SOC RT/TMZ
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- HER2+/HR+ Breast Cancer
- Interventions
- ZW25 (Zanidatamab), Palbociclib, Fulvestrant
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Nashville, Tennessee • Seattle, Washington
- Conditions
- Biliary Tract Cancer
- Interventions
- Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
- Interventions
- Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX, TAS 102, Bevacizumab, Gemcitabine Combined With Cisplatin, NALIRIFOX
- Drug
- Lead sponsor
- Phanes Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- Solid Tumor
- Interventions
- ALG.APV-527
- Drug
- Lead sponsor
- Aptevo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Port Saint Lucie, Florida
- Conditions
- Disseminated Neuroblastoma, Recurrent Neuroblastoma
- Interventions
- IL-2, GD2Bi-aATC, GM-CSF, laboratory evaluations of immune responses
- Biological · Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 13 Months to 29 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • New York, New York • Charlottesville, Virginia
- Conditions
- Food Allergy
- Interventions
- linvoseltamab, dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Atlanta, Georgia • Boston, Massachusetts + 2 more
- Conditions
- Advanced Cancer
- Interventions
- LY3434172
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas